Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06658899 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study of CRD-4730 in CPVT

Study acronym: CPVT
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 9 → 12 locationsv10
  2. Study sites: 8 to 9v9
  3. Study sites: 9 to 8v8
  4. Site details revised at 1 of 9 sitesv7
  5. Study sites: 3 to 9
    • Start date changed from estimate of Dec 2025 to Dec 1, 2025
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    v5
  2. Secondary endpoints: details revised at 2 of 2 entries
    • Study title revised
    v4
  3. Primary and study completion dates: Sep 2026 to Apr 2027
    • Start date: May 2025 to Dec 2025
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 2 of 2 entries
    v3
  4. Secondary endpoints revised (2)
    • Study title revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.
Trial Details
NCT Number NCT06658899
Lead Sponsor Cardurion Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Catecholaminergic Polymorphic Ventricular Tachycardia
Related terms Arrhythmias, Cardiac, Polymorphic Catecholaminergic Ventricular Tachycardia, Tachycardia, Ventricular
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov